Tauriga Sciences Inc. Reports Meaningful Progress With Respect to its Ongoing Pharmaceutical Development Efforts

The Company has finalized the formulation blueprint for its proposed Pharmaceutical Grade Version of Tauri-Gum

NEW YORK, NY, Feb. 18, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today reported meaningful progress in the development of its pharmaceutical grade version of Tauri-Gum.  On January 13, 2020, the Company announced the formation of a wholly owned subsidiary, “Tauriga Pharma Corporation,” to reflect the ongoing development of a pharmaceutical Nausea Regulation (“Anti-Nausea”) product.  The Company has finalized the formulation for this proposed pharmaceutical grade version of Tauri-Gum and is now focused on securing Intellectual Property (“IP”) as well as holding discussion(s) with the Food & Drug Administration (“FDA”).

The Company has retained the law-firm of Lowenstein Sandler (the “Firm”) to represent it, in connection with regulatory matters related to this proposed pharmaceutical product development.  The Company is working directly with the heads of the Firm’s FDA Practice, Chemicals & Life Sciences Patent Practice, and Life Sciences Group.  

The Company will continue to update its shareholders, via press release(s), should there be further progress and/or material event(s) – with respect to these pharmaceutical development efforts. 

ABOUT TAURIGA SCIENCES INC.

Tauriga Sciences, Inc. (TAUG) is a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities. One such opportunity on which the Company has acted, involves the Company having entered into the cannabidiol (or “CBD”) infused chewing gum product business, as more fully described above and in prior press releases.  This CBD infused chewing gum product has been branded under the following name: Tauri-Gum.  The Company is currently in production of three distinct flavors of Tauri-Gum: MINT, BLOOD ORANGE, and POMEGRANATE.  On December 6, 2019 the Company announced that it completed the initial production run (thereby expanding its existing product lines) with the introduction of a 25mg Vegan CBD Isolate Infused vegan gummy (“gum drop”), branded under the name: Tauri-Gummies.  Further, the Company continues to identify and evaluate additional potential opportunities to generate revenue, as well as shareholder value, and leverage its resources and expertise to build a diversified and sustainable business model. Please visit our corporate website at www.tauriga.com.